Elevation Oncology (ELEV) Price & Analysis

Compare

573 Followers

ELEV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $3.09

Previous CloseN/A

Volume1.30M

Average Volume (3M)1.11M

Market Cap

$21.62M

Enterprise Value-$34.07M

Total Cash (Recent Filing)$80.66M

Total Debt (Recent Filing)$31.25M

Price to Earnings (P/E)―

Beta1.33

Next Earnings

Aug 06, 2025

EPS Estimate

-0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding59,224,000

10 Day Avg. Volume1,093,057

30 Day Avg. Volume1,110,916

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-1.58

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit3.79K

Enterprise Value/Ebitda0.71

Forecast

1Y Price Target

$0.37

Price Target Upside2.78% Upside

Rating ConsensusHold

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Acquisition AgreementElevation Oncology's acquisition by Concentra Biosciences includes a cash offer that represents a 12.5% premium to ELEV’s closing price, highlighting a favorable deal for shareholders.

Financial StrategyThe company's strategy to return capital to shareholders efficiently is seen as a positive move to enhance shareholder value.

Shareholder SupportELEV officers, directors, and affiliates, holding about 5.1% of common stock, have agreed to tender their shares, indicating strong insider support for the merger.

Bears Say

Downgraded RatingsThe analyst's recommendation for Elevation Oncology, Inc. stock has been downgraded from Buy to Hold, reflecting a cautious outlook.

Pipeline And Cash ConstraintsELEV's preclinical pipeline and limited cash runway present challenges in establishing a clearly differentiated ADC program.

Strategic And Financial ChallengesThe company faces a difficult financing environment for preclinical biotech and has discontinued development of its lead molecule, EO-3021.

Elevation Oncology News

Elevation Oncology Completes Merger with Concentra Biosciences

Elevation Oncology ( ($ELEV) ) has issued an update. Elevation Oncology, Inc. announced the completion of a merger...

18d ago

ELEV

EO-3021 Study Termination: Implications for Elevation Oncology and Partners

Eli Lilly And Company (($LLY)), GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)), CSPC Pharmaceutical Group (($CHJTF)), Elevation Oncology, Inc....

1M ago

GSK

LLY

Elevation Oncology Terminates License Agreement with CSPC

Elevation Oncology ( ($ELEV) ) has issued an update. On June 26, 2025, Elevation Oncology, Inc. and CSPC...

1M ago

ELEV

Elevation Oncology downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth downgraded Elevation Oncology (ELEV) to Neutral from Buy with a 36c price target...

2M ago

ELEV

Elevation Oncology downgraded to Hold from Buy at TD Cowen

TD Cowen analyst Marc Frahm downgraded Elevation Oncology (ELEV) to Hold from Buy after Concentra Biosciences agreed to...

2M ago

ELEV

Elevation Oncology downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Elevation Oncology (ELEV) to Market Perform from Outperform after Concentra Biosciences agreed to acquire Elevation...

2M ago

ELEV

Elevation Oncology Merges with Concentra Biosciences

An update from Elevation Oncology ( ($ELEV) ) is now available. On June 8, 2025, Elevation Oncology entered...

2M ago

ELEV

Elevation enters into agreement to be acquired by Concentra for 36c per share

Elevation Oncology (ELEV) announced that it has entered into a definitive merger agreement with Concentra Biosciences, whereby Concentra...

2M ago

ELEV

Elevation Oncology: Hold Rating Amid Strategic Uncertainty and Financial Constraints

Analyst Andrew Berens from Leerink Partners maintained a Hold rating on Elevation Oncology (ELEV – Research Report) and...

3M ago

ELEV

Elevation Oncology Reports Q1 2025 Financial Results

Elevation Oncology, Inc. ( ($ELEV) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

ELEV

Elevation Oncology: Strategic Positioning and Financial Stability Drive Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on ELEV stock, giving a Buy rating today....

3M ago

ELEV

Elevation Oncology reports Q1 EPS (24c), consensus (18c)

Estimates that it will have cash, cash equivalents and marketable securities of $30M-$35M as of June 30, 2025,...

3M ago

ELEV

Elevation Oncology’s Chief Medical Officer Steps Down

An update from Elevation Oncology ( ($ELEV) ) is now available. On March 31, 2025, Elevation Oncology announced...

4M ago

ELEV

Boeing upgraded, Lockheed downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5M ago

CAG

ELEV FAQ

What was Elevation Oncology, Inc.’s price range in the past 12 months?

Elevation Oncology, Inc. lowest stock price was $0.22 and its highest was $3.09 in the past 12 months.

What is Elevation Oncology, Inc.’s market cap?

Elevation Oncology, Inc.’s market cap is $21.62M.

When is Elevation Oncology, Inc.’s upcoming earnings report date?

Elevation Oncology, Inc.’s upcoming earnings report date is Aug 06, 2025 which is 4 days ago.

How were Elevation Oncology, Inc.’s earnings last quarter?

Elevation Oncology, Inc. released its earnings results on May 15, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.188 by -$0.052.

Is Elevation Oncology, Inc. overvalued?

According to Wall Street analysts Elevation Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Elevation Oncology, Inc. pay dividends?

Elevation Oncology, Inc. does not currently pay dividends.

What is Elevation Oncology, Inc.’s EPS estimate?

Elevation Oncology, Inc.’s EPS estimate is -0.18.

How many shares outstanding does Elevation Oncology, Inc. have?

Elevation Oncology, Inc. has 59,224,000 shares outstanding.

What happened to Elevation Oncology, Inc.’s price movement after its last earnings report?

Elevation Oncology, Inc. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.188. Following the earnings report the stock price went down -11.765%.

Which hedge fund is a major shareholder of Elevation Oncology, Inc.?

Currently, no hedge funds are holding shares in ELEV

Elevation Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-78.32%

Trailing 12-Months

Asset Growth

-24.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Elevation Oncology, Inc.

Elevation Oncology (ELEV) is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. The company operates in the biotechnology and pharmaceuticals sectors, with a core focus on identifying and developing therapies that target unique genetic drivers of cancer. Elevation Oncology aims to address unmet medical needs by advancing a pipeline of targeted therapies designed to improve patient outcomes in oncology.

Elevation Oncology (ELEV) Earnings & Revenues

Historic Earnings Reports

ELEV Stock 12 Month Forecast

Average Price Target

$0.37

▲(2.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.37</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.36</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.37,0.37076923076923074,0.37153846153846154,0.3723076923076923,0.3730769230769231,0.37384615384615383,0.37461538461538463,0.37538461538461537,0.37615384615384617,0.3769230769230769,0.3776923076923077,0.37846153846153846,0.37923076923076926,{"y":0.38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.37,0.37,0.37,0.37,0.37,0.37,0.37,0.37,0.37,0.37,0.37,0.37,0.37,{"y":0.37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.37,0.36923076923076925,0.36846153846153845,0.3676923076923077,0.3669230769230769,0.36615384615384616,0.36538461538461536,0.3646153846153846,0.3638461538461538,0.3630769230769231,0.3623076923076923,0.36153846153846153,0.36076923076923073,{"y":0.36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.99,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >